Depression

From the impact of patients’ overdose deaths on physicians to addressing America’s mental health crisis, here are highlights from the week in Psychiatric Times.

“We are not exempt from these diseases. We have to speak up.”

"The history of medicine is rich in blaming the disease or the patient for 'untreatable' symptoms, until we stumble upon or develop a treatment that is, in fact, effective."

From special issues in diagnosing and treating catatonia to helping justice-involved individuals re-enter the community, here are highlights from the week in Psychiatric Times.

SPL026 with supportive therapy sees positive results in patients with major depressive disorder.

From a new FDA approval to treating “New Year depression” in patients, here are highlights from the week in Psychiatric Times.

Is inflammation a biomarker of antidepressant efficacy? Researchers analyzed blood CRP levels as a predictor of response to antidepressants.

There may not be a diagnosis for ‘New Year Depression,’ about 10% to 20% of individuals in the US may get a milder form of these winter blues.

Metabolic depression? Researchers performed a metabolomic evaluation of patients with treatment-resistant depression.

Remember to keep the cart behind the horse while practicing medicine.

From new advances in the treatment of postpartum depression to digital therapeutics for the treatment of ADHD in children, here are highlights from the week in Psychiatric Times.

Revisiting the CME articles featured in Psychiatric Times in 2022.

From current treatments for cannabis use disorder to new possibilities for the treatment of dementia, here are highlights from the week in Psychiatric Times.

Cariprazine is now FDA-approved as an adjunctive therapy to antidepressants.

From an in-depth analysis of ADHD in clinical practice to differences in effectiveness between intravenous and intranasal ketamine, here are highlights from the week in Psychiatric Times.

Screening for the symptom of worthlessness could save your adolescent patient’s life…

This latest submission completes the FDA filing that was initiated in May.

Does route of administration affect antidepressant efficacy of ketamine? Researchers performed a meta-analysis of trials comparing intravenous and intranasal administration.

From evidence-based novel therapies for bipolar depression to potential indicators of early-stage Alzheimer disease, here are highlights from the week in Psychiatric Times.

Here’s why most of the claims recently made about antidepressants in Newsweek are wrong.

The drug is in development for the treatment of acute depressive disorders and depression with suicidality.

In this CME article, learn how to apply novel treatment approaches for patients with bipolar depression.

Postpartum depression and major depressive disorder in pregnant and postpartum women are severely underdiagnosed and undertreated. How can we more effectively help this patient population?

Is there one state-of-the-art treatment for depression?